Advent to sell stake in manufacturer and drug developer in a deal worth over $1B — report
After almost three years of investment, private equity firm Advent International may look to sell its part in Bioduro-Sundia.
A Reuters report on Monday detailed that Advent International plans to sell a majority stake in the manufacturing and drug development company that could value the company at over $1 billion, three people with knowledge of the matter told the news site.
However, one of the sources said that a formal sale might not happen until next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.